James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

3 Big Stock Charts for Friday: Kimco Realty, Discovery and Fidelity National Information Services

The stock charts of KIM, FIS and DISCA are set to end the week on the cusp of major moves. Here are the numbers to know.

Amazon’s Home and Furniture Efforts Won’t Hurt Amazon Stock

It's not a reason by itself to buy Amazon stock, but incrementally, it certainly doesn't hurt the bullish case on Amazon stock.

3 Big Stock Charts for Thursday: Pfizer, Coty and Pioneer Natural Resources

The stock charts of COTY, PFE and PXD are worth a closer technical inspection as we move into the latter half of the trading week.

Conagra’s Q3 Earnings Beat Validates Pinnacle Deal

Conagra Brands was in trouble a quarter ago, as the Pinnacle deal got off to a rocky start. That's changed for owners of CAG stock.

8 Genomic Testing Stocks That Can Ease the Sting of Theranos

InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.